Previous 10 | Next 10 |
Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen Therapeutics (NASDAQ:QLGN) +18%. Azu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Virgin Galactic (NYSE: SPCE ) stock is soaring higher on Tuesday after Jefferies analyst Greg Konrad initiated coverage of the company. Source: Christopher Penler / Shutterstock.com Konrad kicked off the firm&...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AC Immune (NASDAQ: ACIU ) stock is rising higher on Tuesday after revealing positive results from an Alzheimer’s disease study. Source: pathdoc / Shutterstock.com The study, which is being conducted by...
AC Immune SA (NASDAQ:ACIU) traded at a new 52-week high today of $12.58. Approximately 9.2 million shares have changed hands today, as compared to an average 30-day volume of 162,000 shares. AC Immune SA (NASDAQ:ACIU) is currently priced 39.4% above its average consensus analyst price ta...
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, ...
Shares of AC Immune (NASDAQ: ACIU) , a clinical-stage biopharmaceutical company, are exploding higher in response to clinical trial results. Investors excited about the company's Alzheimer's disease candidate drove the stock 50.1% higher as of 10:35 a.m. EDT on Tuesday. AC Immun...
Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 First evidence of clinical activity in tau-targeting monoclonal antibody in MMSE 16-21 (mild-to-moderat...
Gainers: CARA +24.3%. CLXT +5.9%. ABNB +3.9%. AMTX +3.9%. ACIU +2.4%. Losers: TBPH -24.1%. XERS -3.0%. CPOP -2.7%. MRIN -2.6%. ALVR -2.1%. For further details see: CARA, CLXT, TBPH and XERS among after hours movers
Announced strategic acquisition of industry-leading Parkinson’s disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE ACI-24 full Phase 1b results presented at AAIC 2021 support the continued clinical development of anti-Abet...
ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) Full Phase 1b results support the continued clinical development of anti-Abeta vaccine approaches in DS-related Alzheimer’s disease (AD) ...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...